-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
On June 28, CStone Pharmaceuticals announced the results of the Chinese patient registration study of the RET inhibitor Pugeta (Platinib) in the global Phase 1/2 ARROW pivotal trial
Pratinib is a potent and selective RET inhibitor developed by CStone Pharmaceuticals partner Blueprint Medicines.
The ARROW study is a global clinical study aimed at evaluating the safety, tolerability and effectiveness of pratinib in patients with RET fusion-positive NSCLC, RET mutant medullary thyroid carcinoma and other advanced solid tumors with RET fusion
Specifically, in 53 patients who had previously received cabozantinib or vandetanib treatment, the objective response rate (ORR) was 60%, one case of remission was to be confirmed, and the median duration of remission (DOR) had not yet been reached
CStone Pharmaceuticals plans to announce the specific data of the registration study at an international academic conference held in the near future
Thyroid cancer is the most common endocrine malignant tumor.
Note: The original text has been deleted
Reference materials:
[1] CStone Pharmaceuticals announced that the registration study of Pugeta® (Platinib Capsules) in Chinese patients with RET mutant medullary thyroid carcinoma (MTC) has reached expectations.
